Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

19 Nov 2009 16:23

RNS Number : 8055C
Plethora Solutions Holdings PLC
19 November 2009
 

PLETHORA SOLUTIONS HOLDINGS PLC

("Plethora" or the "Company")

Directors' dealings

As announced on 18 November 2009, the Directors intend to participate in the Fundraising through the subscription for 1,950,000 new ordinary shares at the placing price of 10p each. In aggregate they will invest £195,000 in the placing, being 12.5% of the Fundraising. The Directors' interests in the Company before and following completion of the Fundraising is set out in the table below.

Number of Ordinary Shares currently held

Number of Ordinary Shares subscribed for

Shares held on Admission of New Ordinary Shares

Options currently held*

Percentage of fully diluted issued share capital

Director

William Robinson

-

1,000,000

1,000,000

-

1.6%

Dr. Steven Powell

4,100

500,000

504,100

1,334,951

2.9%

Dr. Mike Wyllie

486,494

200,000

686,494

724,491

2.3%

Ronald Openshaw

-

250,000

250,000

-

0.4%

*All options held are exercisable at between 59p and 202p

Following the Fundraising, the total enlarged issued share capital of the Company will b41,965,800 and no ordinary shares will be held in treasury. Therefore, following the Placing, the total number of voting rights in the Company will be 41,965,800. The above figure may be used by shareholders in determining whether they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules. 

 

Enquiries:

Plethora Solutions

Steven Powell Tel : +44(0) 20 3077 5400

FinnCap

Geoff Nash/Marc Young Tel : +44(0) 20 7600 1658

Hansard Group

Adam Reynolds/John Bick Tel: +44(0) 20 7245 1100

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE) 

Further information is available at www.plethorasolutions.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSILFFRLLLALIA
Date   Source Headline
30th Sep 20087:00 amRNSInterim Results
30th Sep 20087:00 amRNSClinical Update - PSD502
11th Aug 20087:00 amRNSBoard Change
21st Jul 20082:20 pmRNSHolding(s) in Company
1st Jul 20087:05 amRNSDirector/PDMR Shareholding
1st Jul 20087:00 amRNSChange of Adviser
27th Jun 20087:00 amRNSBoard Change
23rd Jun 20082:44 pmRNSAGM Statement
19th Jun 20087:00 amRNSClinical Update PSD502 Phase
22nd May 200810:00 amRNSAnnual Report and Accounts
29th Apr 20087:00 amRNSFinal Results
24th Apr 20087:00 amRNSClinical Update - PSD508
21st Apr 200811:13 amRNSNotice of Results
1st Apr 20087:01 amRNSRe $28m Financing
10th Mar 20085:49 pmRNSHolding(s) in Company
5th Feb 20087:00 amRNSClinical Update - PSD506
10th Jan 200810:39 amRNSChange of Registered Office
19th Dec 20077:01 amRNSClinical Update - PSD502
6th Dec 20077:00 amRNSClinical Update - PSD508
29th Nov 20077:01 amRNSClinical Update PSD503
30th Oct 200712:30 pmBUSSciele Pharma and Plethora Solutions Holdings PLC Announce Initiation of Pivotal Phase III Trials for PSD502 for Premature Ejaculation
30th Oct 20077:01 amRNSClinical Update PSD502 Ph III
8th Oct 20077:00 amRNSClinical Update PSD597
26th Sep 20077:02 amRNSInterim Results
25th Sep 20074:55 pmRNSHolding(s) in Company
10th Sep 20079:27 amRNSNotice of Results
6th Sep 20077:01 amRNSClinical Update PSD597
16th Aug 20072:44 pmRNSAIM Rule 26
12th Jul 20077:01 amRNSClinical Update - PSD502
10th Jul 20074:11 pmRNSResult of AGM
2nd Jul 20073:14 pmRNSDirector/PDMR Shareholding
2nd Jul 20077:01 amRNSProduct Update - Invicorp
29th Jun 20071:20 pmRNSTotal Voting Rights
29th Jun 200710:29 amRNSShare Options Award
25th Jun 20077:01 amRNSClinical Update PSD597 for IC
14th Jun 20074:46 pmRNSHolding(s) in Company
14th Jun 20074:39 pmRNSHolding(s) in Company
1st Jun 200710:00 amRNSDirectorate Change
30th May 20077:01 amRNSPreliminary Results
24th May 20071:00 pmBUSSciele Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation
24th May 20077:05 amRNSNotice of Results
24th May 20077:03 amRNSLicensing deal
8th May 20077:02 amRNSProduct Acquisitions
5th Apr 20077:36 amRNSAcquisition
21st Mar 20075:05 pmRNSHolding(s) in Company
21st Mar 20075:05 pmRNSHolding(s) in Company
21st Mar 20075:04 pmRNSHolding(s) in Company
13th Mar 20071:08 pmRNSHolding(s) in Company
12th Mar 20072:16 pmRNSExercise of share options
1st Mar 20077:03 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.